Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II clinical trial of repurposed Nylexa as a COVID-19 therapy

Next Previous
Trial Profile

Phase II clinical trial of repurposed Nylexa as a COVID-19 therapy

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 23 Oct 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mercaptamine (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions

Most Recent Events

  • 16 Oct 2020 According to an NovaBiotics media release, the company it has secured 1 million pound in funding from Innovate UK to commence clinical studies for Nylexa for the treatment of COVID-19.
  • 15 Apr 2020 New trial record
  • 13 Apr 2020 According to an NovaBiotics media release, in partnership with the NHS and subject to MHRA and ethics committee approvals, clinical studies could get underway in a very short space of time in patients hospitalised with COVID-19. The company anticipates that subject to positive trial results, the use of Nylexa will continue on a named patient /compassionate use basis during the outbreak beyond the trial in the UK and other countries.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top